Investing carries serious risks, including partial or total loss of capital. Please read the Information Note and the Risk factors and login before investing.

Leaphy

Equity Belgium 54 investors Tax Shelter applicable

Sustainable Development Tax Shelter

Leaphy, the single trusted source for information about medicines and more
Information Note Terms & Conditions
€2,900,000
Pre money valuation
23.7%
Equity offered
€40,100
Amount raised
47 days
Remaining
€50,000
Minimum target
80% funded

Geert De Pelsmaeker

CEO

Geert De Pelsmaeker has a Masters in nursing, health economics (university of Brussel) VUB) and and in Business Management (University of KU Leuven). He started his career in the pharmaceutical industry where he had several positions in sales and marketing. He launched Zolpidem (Stilnoct) in the Belgian Market. In 1995 he started his own company in CRM for the pharmaceutical industry. He was successful with this product whole over Europe. When this company was bought by Dendride (IMS now). Afterwards he started a new company “MedDb” for medical and pharmaceutical data management

Guilherme Monteiro Ferreira

Board member

Guilherme Monteiro Ferreira is a pharmacist by education (University of Lisbon). Gui has more than 7 years of experience in public and governmental affairs. In addition he has a large network of European pharmacists due to several years of involvement in the European Pharmaceutical Students Association (EPSA). Gui is, as a board member, strategic adviser and will become COO of Leaphy, supporting the country expansion.

Maarten Van Baelen

Board member

Maarten Van Baelen is a pharmacists by education (KU Leuven) and holds a Master in Business Administration from Solvay Business School (Brussels) and École des Ponts (Paris). Maarten worked for more than 12 years in the pharmaceutical industry. In the past he has been involved in the foundations of non-profit organisations such as LMS Events and the European Medicines Verification Organisation (EMVO). Maarten has developed the Leaphy business plan and is, as board member, strategic adviser to Leaphy.

TAX SHELTER 45%

This business qualifies for the startup tax shelter. If you meet the conditions, 45% of your investment will be reducted from your personal income taxes. Read more…